JP6433986B2 - 免疫グロブリン単一可変ドメインの安定製剤及びその使用 - Google Patents

免疫グロブリン単一可変ドメインの安定製剤及びその使用 Download PDF

Info

Publication number
JP6433986B2
JP6433986B2 JP2016513387A JP2016513387A JP6433986B2 JP 6433986 B2 JP6433986 B2 JP 6433986B2 JP 2016513387 A JP2016513387 A JP 2016513387A JP 2016513387 A JP2016513387 A JP 2016513387A JP 6433986 B2 JP6433986 B2 JP 6433986B2
Authority
JP
Japan
Prior art keywords
formulation
concentration
vwf
formulations
storage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016513387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520075A (ja
JP2016520075A5 (enExample
Inventor
メイヴィス，イヴ
デ・ブラバンデレ，ヴェロニク
ウルリヒトシュ，ハンス
ブリジ，アン
カルヴァエール，フィリップ
Original Assignee
アブリンクス エン．ヴェー．
アブリンクス エン．ヴェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブリンクス エン．ヴェー．, アブリンクス エン．ヴェー． filed Critical アブリンクス エン．ヴェー．
Publication of JP2016520075A publication Critical patent/JP2016520075A/ja
Publication of JP2016520075A5 publication Critical patent/JP2016520075A5/ja
Priority to JP2018209611A priority Critical patent/JP6952019B2/ja
Application granted granted Critical
Publication of JP6433986B2 publication Critical patent/JP6433986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016513387A 2013-05-17 2014-05-16 免疫グロブリン単一可変ドメインの安定製剤及びその使用 Active JP6433986B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018209611A JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824523P 2013-05-17 2013-05-17
US61/824,523 2013-05-17
PCT/EP2014/060107 WO2014184352A1 (en) 2013-05-17 2014-05-16 Stable formulations of immunoglobulin single variable domains and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018209611A Division JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Publications (3)

Publication Number Publication Date
JP2016520075A JP2016520075A (ja) 2016-07-11
JP2016520075A5 JP2016520075A5 (enExample) 2017-06-15
JP6433986B2 true JP6433986B2 (ja) 2018-12-05

Family

ID=49304267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016513387A Active JP6433986B2 (ja) 2013-05-17 2014-05-16 免疫グロブリン単一可変ドメインの安定製剤及びその使用
JP2018209611A Active JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018209611A Active JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Country Status (25)

Country Link
US (2) US10035862B2 (enExample)
EP (2) EP2996720B1 (enExample)
JP (2) JP6433986B2 (enExample)
KR (1) KR102166399B1 (enExample)
CN (3) CN110063935B (enExample)
AU (3) AU2014267222B2 (enExample)
BR (1) BR112015028411B1 (enExample)
CA (1) CA2912670A1 (enExample)
CY (1) CY1122090T1 (enExample)
DK (1) DK2996720T3 (enExample)
ES (2) ES2895150T3 (enExample)
HR (1) HRP20190954T1 (enExample)
HU (1) HUE044392T2 (enExample)
LT (1) LT2996720T (enExample)
MX (2) MX387527B (enExample)
NL (1) NL1040254C2 (enExample)
PH (1) PH12015502591A1 (enExample)
PL (2) PL3511018T3 (enExample)
PT (2) PT2996720T (enExample)
RS (1) RS58857B1 (enExample)
RU (1) RU2671977C2 (enExample)
SI (1) SI2996720T1 (enExample)
SM (1) SMT201900359T1 (enExample)
TR (1) TR201908663T4 (enExample)
WO (1) WO2014184352A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019034967A (ja) * 2013-05-17 2019-03-07 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3233910T (pt) 2014-12-19 2020-03-17 Ablynx Nv Dímeros de nanocorpos ligados a cisteína
CN105833255A (zh) * 2016-03-23 2016-08-10 兆科药业（合肥）有限公司 抗血小板溶栓素在制备治疗血栓性血小板减少性紫癜的药物中的应用
GB201612043D0 (en) 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
EP3534963B1 (en) * 2016-11-02 2024-04-17 Polaris Group Formulations of pegylated arginine deiminase
AU2019217584B2 (en) 2018-02-06 2025-08-14 Ablynx Nv Methods of treating initial episode of TTP with immunoglobulin single variable domains
MX2020013734A (es) 2018-07-03 2021-05-27 Fennec Pharmaceuticals Inc Formulaciones de tiosulfato de sodio anhidro.
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
CN112839683B (zh) * 2018-10-10 2023-11-14 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
CN110564841A (zh) * 2019-09-19 2019-12-13 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 脑缺血相关基因作为缺血性卒中行为学特征分析的生物标记的应用
CN110624105B (zh) * 2019-09-24 2021-06-11 苏州大学 血管性血友病因子的结构敏感多肽抗原的序列
JP7502861B2 (ja) * 2019-12-27 2024-06-19 旭化成株式会社 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法
CN113908254B (zh) * 2021-10-19 2024-05-28 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
CN115850493B (zh) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 一种二价纳米抗体Cablivi的分离纯化方法
WO2025240928A1 (en) * 2024-05-16 2025-11-20 Vega Therapeutics, Inc. Treatment of von willebrand disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
CA2190502A1 (en) 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
WO2000046383A2 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
CA2367955C (en) 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
BR0011753A (pt) 1999-06-18 2002-04-30 Cv Therapeutics Inc Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp
EP1198572A2 (en) 1999-08-02 2002-04-24 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
EP1233987B1 (en) 1999-11-29 2009-08-19 Bac Ip B.V. Immobilized single domain antigen-binding molecules
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
DK1360207T3 (da) 2000-12-13 2011-09-05 Bac Ip B V Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler
DK1419179T3 (da) 2001-08-10 2010-06-21 Univ Aberdeen Antigenbindingsdomæner fra fisk
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
WO2003054016A2 (en) 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
JP2006512910A (ja) 2002-10-23 2006-04-20 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ａ３４およびａ３３様３ｄｎａ、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
AU2006205900B8 (en) 2005-01-14 2012-04-05 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
CN101262885B (zh) * 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
UA96473C2 (ru) * 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
JP5784907B2 (ja) * 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 組換え型ｖｗｆ製剤
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
AU2009227055A1 (en) * 2008-03-21 2009-09-24 Ablynx Nv Von Willebrand Factor specific binders and methods of use therefor
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
AR074054A1 (es) * 2008-10-21 2010-12-22 Baxter Healthcare Sa Formulaciones farmaceuticas de factor de von willebrand recombinante liofilizado
EP4104821A1 (en) * 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2011067160A1 (en) 2009-12-01 2011-06-09 Ablynx Nv Von willebrand factor specific binding agents and uses thereof
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CN102753148B (zh) * 2010-02-11 2018-01-26 埃博灵克斯股份有限公司 用于制备气雾剂的方法和组合物
US20120225072A1 (en) * 2011-03-02 2012-09-06 Ablynx N.V. Stable formulations of immunoglobulin single variable domains and uses thereof
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019034967A (ja) * 2013-05-17 2019-03-07 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Also Published As

Publication number Publication date
BR112015028411A2 (pt) 2017-12-12
PL2996720T3 (pl) 2019-09-30
AU2019201307A1 (en) 2019-03-14
SMT201900359T1 (it) 2019-07-11
HK1218258A1 (zh) 2017-02-10
DK2996720T3 (da) 2019-06-24
EP2996720B1 (en) 2019-03-27
US20160090424A1 (en) 2016-03-31
CN110063935B (zh) 2021-11-09
MX364664B (es) 2019-05-03
AU2014267222B2 (en) 2018-12-13
WO2014184352A1 (en) 2014-11-20
TR201908663T4 (tr) 2019-07-22
RU2018137504A3 (enExample) 2021-12-28
EP3511018A1 (en) 2019-07-17
NL1040254C2 (en) 2014-11-24
RS58857B1 (sr) 2019-07-31
AU2021200035A1 (en) 2021-02-25
RU2015154214A (ru) 2017-06-22
JP2016520075A (ja) 2016-07-11
PH12015502591B1 (en) 2016-02-29
JP2019034967A (ja) 2019-03-07
AU2014267222A1 (en) 2015-11-12
EP2996720A1 (en) 2016-03-23
ES2731922T3 (es) 2019-11-19
CN110037983A (zh) 2019-07-23
KR102166399B1 (ko) 2020-10-16
CA2912670A1 (en) 2014-11-20
SI2996720T1 (sl) 2019-07-31
LT2996720T (lt) 2019-07-10
ES2895150T3 (es) 2022-02-17
HUE044392T2 (hu) 2019-10-28
RU2671977C2 (ru) 2018-11-08
PL3511018T3 (pl) 2022-01-10
MX2019005269A (es) 2019-09-04
US20190010249A1 (en) 2019-01-10
PH12015502591A1 (en) 2016-02-29
MX387527B (es) 2025-03-12
CN110063935A (zh) 2019-07-30
HRP20190954T1 (hr) 2019-07-26
BR112015028411B1 (pt) 2023-01-10
KR20160007657A (ko) 2016-01-20
MX2015015722A (es) 2016-03-16
RU2018137504A (ru) 2018-12-14
PT3511018T (pt) 2021-10-15
CY1122090T1 (el) 2020-11-25
CN105339003B (zh) 2018-11-20
EP3511018B1 (en) 2021-07-28
JP6952019B2 (ja) 2021-10-20
US10035862B2 (en) 2018-07-31
CN105339003A (zh) 2016-02-17
AU2019201307B2 (en) 2021-01-28
PT2996720T (pt) 2019-07-04

Similar Documents

Publication Publication Date Title
JP6952019B2 (ja) 免疫グロブリン単一可変ドメインの安定製剤及びその使用
EP3438126B1 (en) Stable formulations of polypeptides and uses thereof
JP2025160348A (ja) タンパク質製剤
US20180155441A1 (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
RU2773172C2 (ru) Стабильные композиции иммуноглобулинового одиночного вариабельного домена и их применение
US20120225072A1 (en) Stable formulations of immunoglobulin single variable domains and uses thereof
HK1218258B (zh) 免疫球蛋白单可变结构域的稳定制剂及其应用
KR20230121797A (ko) 항-il5r 항체 제형

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181107

R150 Certificate of patent or registration of utility model

Ref document number: 6433986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250